



PRESS RELEASE

September 5, 2024

Ziccum CEO Analyst video interview: Q2, 2024 highlights

Watch Ziccum CEO Ann Gidner in a comprehensive interview in Swedish with analyst Jonathan Furelid on the highlights of Ziccum's Q2 2024 report and the company's current and coming status.

CEO Ann Gidner provides investors with updates and insights on further mRNA/LNP milestones, including the recently disclosed significant mRNA activity increase with LaminarPace, the status of Ziccum's current partner projects including the newly signed ReCode Therapeutics deal, the growing industry-wide interest for Ziccum and the progress in solidifying Ziccum's intellectual property protection.

You may watch the interview here: <https://youtu.be/6ttsdxZh6UM>

For more information about Ziccum, please contact:

Ann Gidner
CEO, Ziccum AB
Mail: gidner@ziccum.com
Mobile: +46 722140141

Jonas Ekblom
Chairman of the Board, Ziccum AB
Mail: ekblom@ziccum.com
Mobile: +46 736777540

Ziccum's Certified Adviser is
Carnegie Investment Bank AB (publ)
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum CEO Analyst video interview: Q2, 2024 highlights](#)